[{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"e098103f-75c1-4aa9-b386-41c1d51fb602","acronym":"MATCH","url":"https://clinicaltrials.gov/study/NCT03155620","created_at":"2021-01-18T15:33:32.929Z","updated_at":"2025-02-25T16:51:52.930Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)","source_id_and_acronym":"NCT03155620 - MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Vitrakvi (larotrectinib) • Koselugo (selumetinib) • Balversa (erdafitinib) • Retevmo (selpercatinib) • Ensacove (ensartinib) • Zarnestra (tipifarnib) • Tazverik (tazemetostat) • ulixertinib (BVD-523) • samotolisib (LY3023414)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2316","initiation":"Initiation: 07/31/2017","start_date":" 07/31/2017","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-04"},{"id":"4a7a80ea-21b3-4d81-8f03-943129f3e58b","acronym":"KURRENT-HN","url":"https://clinicaltrials.gov/study/NCT04997902","created_at":"2021-08-10T14:52:48.661Z","updated_at":"2024-07-02T16:35:31.801Z","phase":"Phase 1/2","brief_title":"Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)","source_id_and_acronym":"NCT04997902 - KURRENT-HN","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" PIK3CA • HRAS","pipe":"","alterations":" ","tags":["PIK3CA • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • Zarnestra (tipifarnib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-25"},{"id":"97348d3c-50dc-4afa-b18a-6e0c3e18c9b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05693090","created_at":"2023-01-20T14:59:55.661Z","updated_at":"2024-07-02T16:35:54.005Z","phase":"Phase 1","brief_title":"Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05693090","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Zarnestra (tipifarnib)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 07/27/2027","primary_completion_date":" 07/27/2027","study_txt":" Completion: 07/27/2027","study_completion_date":" 07/27/2027","last_update_posted":"2023-03-06"},{"id":"eedda5a0-ec8c-4127-bb15-acd6b4c60d96","acronym":"SEQ-HN","url":"https://clinicaltrials.gov/study/NCT03719690","created_at":"2021-01-18T18:13:51.350Z","updated_at":"2024-07-02T16:36:00.691Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy","source_id_and_acronym":"NCT03719690 - SEQ-HN","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" HRAS","pipe":" | ","alterations":" RAS wild-type • HRAS mutation • HRAS wild-type","tags":["HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type • HRAS mutation • HRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 284","initiation":"Initiation: 11/05/2018","start_date":" 11/05/2018","primary_txt":" Primary completion: 05/30/2023","primary_completion_date":" 05/30/2023","study_txt":" Completion: 05/31/2023","study_completion_date":" 05/31/2023","last_update_posted":"2022-11-09"},{"id":"71f1c969-b84a-461e-abff-6a5fd7a94ebc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02535650","created_at":"2021-01-17T17:10:25.985Z","updated_at":"2024-07-02T16:36:15.904Z","phase":"Phase 2","brief_title":"Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma","source_id_and_acronym":"NCT02535650","lead_sponsor":"Samsung Medical Center","biomarkers":" STK11 • HRAS","pipe":" | ","alterations":" STK11 mutation • HRAS mutation","tags":["STK11 • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e STK11 mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 11/12/2015","start_date":" 11/12/2015","primary_txt":" Primary completion: 03/01/2022","primary_completion_date":" 03/01/2022","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2022-03-08"},{"id":"05393640-65bf-4e1a-874e-2d7c1305fa9f","acronym":"KO-TIP-001","url":"https://clinicaltrials.gov/study/NCT02383927","created_at":"2021-01-17T17:10:25.340Z","updated_at":"2024-07-02T16:36:30.260Z","phase":"Phase 2","brief_title":"Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations","source_id_and_acronym":"NCT02383927 - KO-TIP-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" HRAS","pipe":" | ","alterations":" HRAS mutation","tags":["HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 03/01/2015","start_date":" 03/01/2015","primary_txt":" Primary completion: 11/30/2020","primary_completion_date":" 11/30/2020","study_txt":" Completion: 11/30/2020","study_completion_date":" 11/30/2020","last_update_posted":"2021-05-14"},{"id":"ef305389-9686-430a-961c-050929e8a0a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02807272","created_at":"2021-01-18T13:46:04.937Z","updated_at":"2024-07-02T16:36:30.264Z","phase":"Phase 2","brief_title":"Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia","source_id_and_acronym":"NCT02807272","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • CXCR4 • CXCR2","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type • CXCR4 expression","tags":["KRAS • NRAS • CXCR4 • CXCR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type • CXCR4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 45","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 12/14/2020","primary_completion_date":" 12/14/2020","study_txt":" Completion: 12/14/2020","study_completion_date":" 12/14/2020","last_update_posted":"2021-05-14"},{"id":"541b6e15-f680-4fed-875c-89d65027c712","acronym":"","url":"https://clinicaltrials.gov/study/NCT02464228","created_at":"2021-01-17T17:51:01.848Z","updated_at":"2024-07-02T16:36:31.197Z","phase":"Phase 2","brief_title":"Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy.","source_id_and_acronym":"NCT02464228","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" ALK • CXCL12","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • CXCL12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 10/08/2015","start_date":" 10/08/2015","primary_txt":" Primary completion: 03/24/2021","primary_completion_date":" 03/24/2021","study_txt":" Completion: 03/24/2021","study_completion_date":" 03/24/2021","last_update_posted":"2021-04-27"},{"id":"fd9fbd7f-ee3d-4043-9831-01acedf500b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00470301","created_at":"2021-01-18T01:40:22.121Z","updated_at":"2024-07-02T16:36:34.566Z","phase":"Phase 1/2","brief_title":"Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer","source_id_and_acronym":"NCT00470301","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative • PGR positive • PGR negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Zarnestra (tipifarnib) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 04/01/2007","start_date":" 04/01/2007","primary_txt":" Primary completion: 09/01/2013","primary_completion_date":" 09/01/2013","study_txt":" Completion: 09/01/2013","study_completion_date":" 09/01/2013","last_update_posted":"2021-02-16"},{"id":"8a8d1435-ca0f-4ed3-945a-9e674dc58043","acronym":"","url":"https://clinicaltrials.gov/study/NCT00082810","created_at":"2021-01-18T00:14:04.073Z","updated_at":"2024-07-02T16:37:05.650Z","phase":"Phase 2","brief_title":"Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT00082810","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PGR","pipe":"","alterations":" ","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 07/01/2008","primary_completion_date":" 07/01/2008","study_txt":" Completion: 09/01/2008","study_completion_date":" 09/01/2008","last_update_posted":"2018-11-01"},{"id":"61d3072d-b3e5-468f-b9bd-37180e632549","acronym":"","url":"https://clinicaltrials.gov/study/NCT00335764","created_at":"2021-01-18T01:09:35.900Z","updated_at":"2024-07-02T16:37:09.330Z","phase":"Phase 1/2","brief_title":"Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma","source_id_and_acronym":"NCT00335764","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • sorafenib • temsirolimus • Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 92","initiation":"Initiation: 04/01/2006","start_date":" 04/01/2006","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 09/01/2012","study_completion_date":" 09/01/2012","last_update_posted":"2018-07-02"},{"id":"01a7c4c6-036a-451b-8238-01cffd6ac6b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02210858","created_at":"2021-01-18T10:21:21.648Z","updated_at":"2024-07-02T16:37:10.333Z","phase":"Phase 1/2","brief_title":"Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders","source_id_and_acronym":"NCT02210858","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ABL1 • BCR","pipe":" | ","alterations":" KRAS mutation • RAS mutation","tags":["KRAS • ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 05/01/2000","start_date":" 05/01/2000","primary_txt":" Primary completion: 11/12/2004","primary_completion_date":" 11/12/2004","study_txt":" Completion: 03/01/2017","study_completion_date":" 03/01/2017","last_update_posted":"2018-06-04"},{"id":"cb38c596-a6ea-4952-8fa0-5dd394d19664","acronym":"","url":"https://clinicaltrials.gov/study/NCT00076102","created_at":"2021-01-18T00:12:16.073Z","updated_at":"2024-07-02T16:37:11.304Z","phase":"Phase 2","brief_title":"Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas","source_id_and_acronym":"NCT00076102","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 07/21/2004","start_date":" 07/21/2004","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":" Completion: 04/01/2010","study_completion_date":" 04/01/2010","last_update_posted":"2018-04-23"},{"id":"c61ee56b-8ad9-4c81-89b2-8429da8db63a","acronym":"","url":"https://clinicaltrials.gov/study/NCT00021541","created_at":"2021-01-17T23:57:48.574Z","updated_at":"2024-07-02T16:37:11.457Z","phase":"Phase 2","brief_title":"R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas","source_id_and_acronym":"NCT00021541","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 62","initiation":"Initiation: 07/17/2001","start_date":" 07/17/2001","primary_txt":" Primary completion: 02/19/2009","primary_completion_date":" 02/19/2009","study_txt":" Completion: 02/19/2009","study_completion_date":" 02/19/2009","last_update_posted":"2018-04-17"},{"id":"c348c65a-870f-40cf-88ec-7ac6203600f2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00678951","created_at":"2021-01-18T02:32:16.777Z","updated_at":"2024-07-02T16:37:16.654Z","phase":"Phase 2","brief_title":"Pegintron to Treat Plexiform Neurofibromas in Children and Young Adults","source_id_and_acronym":"NCT00678951","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib) • ViraferonPeg (peginterferon-α-2b)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 05/01/2008","start_date":" 05/01/2008","primary_txt":" Primary completion: 01/01/2016","primary_completion_date":" 01/01/2016","study_txt":" Completion: 01/01/2016","study_completion_date":" 01/01/2016","last_update_posted":"2017-11-06"},{"id":"8a095384-8795-49e2-975e-166b35eb9264","acronym":"","url":"https://clinicaltrials.gov/study/NCT00331591","created_at":"2021-01-18T01:08:40.620Z","updated_at":"2024-07-02T16:37:23.802Z","phase":"Phase 2","brief_title":"Response to Tipifarnib in Individuals With Large Granular Lymphocyte Leukemia","source_id_and_acronym":"NCT00331591","lead_sponsor":"Office of Rare Diseases (ORD)","biomarkers":" CD8 • B3GAT1","pipe":"","alterations":" ","tags":["CD8 • B3GAT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zarnestra (tipifarnib)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 05/01/2006","start_date":" 05/01/2006","primary_txt":" Primary completion: 05/01/2007","primary_completion_date":" 05/01/2007","study_txt":" Completion: 05/01/2007","study_completion_date":" 05/01/2007","last_update_posted":"2017-04-05"}]